Predictive value of FDG‐PET imaging for relapse in metastatic melanoma patients treated with immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Predictive value of FDG‐PET imaging for relapse in metastatic melanoma patients treated with immunotherapy

Published:2020-07 Issue:10 Volume:34 Page:2261-2267
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Mesnard C.¹,Bodet‐Milin C.²³,Eugène T.²³,Nguyen J‐M.⁴,Khammari A.¹,Dréno B.¹^ORCID

Affiliation:

1. Department of Dermatology CHU Nantes CRCINA Université de Nantes Nantes France

2. Department of Nuclear Medicine CHU Nantes Nantes France

3. CRCINA INSERM CNRS Université d'Angers Université de Nantes Nantes France

4. Department of Epidemiology and Biostatistics CHU Nantes CRCINA INSERM Université de Nantes Nantes France

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.16358

Reference27 articles.

1. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

2. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

3. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

4. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

5. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis;eClinicalMedicine;2024-07

2. The predictive power of FDG‐PET imaging with regard to immunotherapy in real‐life conditions in advanced melanoma: An exploratory study;Journal of the European Academy of Dermatology and Venereology;2022-08-24

3. Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial;ESMO Open;2022-02

4. FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma;Annals of Oncology;2022-01

5. Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma Patients;Journal of Immunotherapy;2021-05-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3